Overexpression of Lrp5 enhanced the anti-breast cancer effects of osteocytes in bone

Abstract

Osteocytes are the most abundant cells in bone, which is a frequent site of breast cancer metastasis. Here, we focused on Wnt signaling and evaluated tumor-osteocyte interactions. In animal experiments, mammary tumor cells were inoculated into the mammary fat pad and tibia. The role of Lrp5-mediated Wnt signaling was examined by overexpressing and silencing Lrp5 in osteocytes and establishing a conditional knockout mouse model. The results revealed that administration of osteocytes or their conditioned medium (CM) inhibited tumor progression and osteolysis. Osteocytes overexpressing Lrp5 or β-catenin displayed strikingly elevated tumor-suppressive activity, accompanied by downregulation of tumor-promoting chemokines and upregulation of apoptosis-inducing and tumor-suppressing proteins such as p53. The antitumor effect was also observed with osteocyte-derived CM that was pretreated with a Wnt-activating compound. Notably, silencing Lrp5 in tumors inhibited tumor progression, while silencing Lrp5 in osteocytes in conditional knockout mice promoted tumor progression. Osteocytes exhibited elevated Lrp5 expression in response to tumor cells, implying that osteocytes protect bone through canonical Wnt signaling. Thus, our results suggest that the Lrp5/β-catenin axis activates tumor-promoting signaling in tumor cells but tumor-suppressive signaling in osteocytes. We envision that osteocytes with Wnt activation potentially offer a novel cell-based therapy for breast cancer and osteolytic bone metastasis.

References

[1] Weigelt B et al. Breast cancer metastasis: markers and models. Nat. Rev. Cancer, 2005, 5: 591-602

[2] Macedo F et al. Bone metastases: an overview. Oncol. Rev., 2017, 11: 321

[3] Xiong Z et al. Bone metastasis pattern in initial metastatic breast cancer: a population-based study. Cancer Manag Res., 2018, 10: 287-295

[4] Wu Q et al. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. Oncotarget, 2017, 8: 27990-27996

[5] Buijs JT et al. TGF-beta in the bone microenvironment: role in breast cancer metastases. Cancer Microenviron., 2011, 4: 261-281

[6] Goldring SR. The osteocyte: key player in regulating bone turnover. RMD Open., 2015, 1: e000049

[7] Sapir-Koren R, Livshits G. Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles? Osteoporos. Int., 2014, 25: 2685-2700

[8] Dallas SL, Prideaux M, Bonewald LF. The osteocyte: an endocrine cell… and more. Endocr. Rev., 2013, 34: 658-690

[9] Gao H et al. Lowlevel mechanical vibration enhances osteoblastogenesis via a canonical Wnt signalingassociated mechanism. Mol. Med Rep., 2017, 16: 317-324

[10] Klein-Nulend J et al. Mechanosensation and transduction in osteocytes. Bone, 2013, 54: 182-190

[11] Sawakami K et al. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J. Biol. Chem., 2006, 281: 23698-23711

[12] MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell., 2009, 17: 9-26

[13] Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer, 2013, 13: 11-26

[14] Ella B et al. Ronit Shtrichman Cell-based therapy approaches: the hope for incurable diseases. Regen. Med., 2014, 9: 649-672

[15] Joseph A et al. Mesenchymal stem cell-conditioned media: a novel alternative of stem cell therapy for quality wound healing. J. Cell Physiol., 2020, 235: 5555-5569

[16] Parker TM et al. Cell competition and tumor heterogeneity. Semin Cancer Biol., 2020, 63: 1-10

[17] Homare E et al. Regulation of sclerostin expression in multiple myeloma by Dkk-1: a potential therapeutic strategy for myeloma bone disease. J. Bone Min. Res., 2016, 31: 1225-1234

[18] Delgado-Calle J et al. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. Leukemia, 2017, 31: 2686-2694

[19] Wang N et al. CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-kappaB/SOX4 signaling. Cell Death Dis., 2018, 9

[20] Hsu YL et al. Breast tumor-associated osteoblast-derived CXCL5 increases cancer progression by ERK/MSK1/Elk-1/snail signaling pathway. Oncogene, 2013, 32: 4436-4447

[21] Di J et al. Identification of WISP1 as a novel oncogene in glioblastoma. Int. J. Oncol., 2017, 51: 1261-1270

[22] Ikuno U, Nobuyuki T. Role of p53 in the regulation of the inflammatory tumor microenvironment and tumor suppression. Cancers, 2018, 10: 219

[23] Yu X, Harris SL, Levine AJ. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res., 2006, 66: 4795-4801

[24] Prasad M et al. Dual TGFbeta/BMP pathway inhibition enables expansion and characterization of multiple epithelial cell types of the normal and cancerous breast. Mol. Cancer Res., 2019, 17: 1556-1570

[25] Yousef EM et al. MMP-9 expression varies according to molecular subtypes of breast cancer. BMC Cancer, 2014, 14

[26] Ferrari N et al. RUNX2 in mammary gland development and breast cancer. J. Cell Physiol., 2013, 228: 1137-1142

[27] Bram DC, Geert B. Snail in the frame of malignant tumor recurrence. Breast Cancer Res., 2006, 8

[28] Zhao X et al. TRIP6 enhances stemness property of breast cancer cells through activation of Wnt/beta-catenin. Cancer Cell Int., 2020, 20

[29] Martin M et al. Mechanobiological osteocyte feedback drives mechanostat regulation of bone in a multiscale computational model. Biomech. Model Mechanobiol., 2019, 18: 1475-1496

[30] Wang L, Wang FS. Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges. Hepatol. Int., 2019, 13: 521-533

[31] Sekita A, Matsugaki A, Nakano T. Disruption of collagen/apatite alignment impairs bone mechanical function in osteoblastic metastasis induced by prostate cancer. Bone, 2017, 97: 83-93

[32] Ulsperger E et al. Effects of 1alpha,25-dihydroxy-vitamin D3 pretreatment and MAP kinase inhibitor PD 98059 on response of osteoblasts to prostate-derived osteoblastic factors. Oncol. Rep., 2003, 10: 1529-1534

[33] Wang W et al. Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion. Oncogene, 2019, 38: 4540-4559

[34] Ewens A, Mihich E, Ehrke MJ. Distant metastasis from subcutaneously grown E0771 medullary breast adenocarcinoma. Anticancer Res., 2005, 25: 3905-3915

[35] Tai S et al. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate, 2011, 71: 1668-1679

[36] Chen A et al. Attraction and compaction of migratory breast cancer cells by bone matrix proteins through tumor-osteocyte interactions. Sci. Rep., 2018, 8

[37] Xu W et al. Suppressed invasive and migratory behaviors of SW1353 chondrosarcoma cells through the regulation of Src, Rac1 GTPase, and MMP13. Cell Signal., 2015, 27: 2332-2342

[38] Liu S et al. Osteocyte-driven downregulation of snail restrains effects of Drd2 inhibitors on mammary tumor cells. Cancer Res., 2018, 78: 3865-3876

[39] Li F et al. Vinculin force sensor detects tumor-osteocyte interactions. Sci. Rep., 2019, 9

[40] Zhao L et al. Inactivation of Lrp5 in osteocytes reduces young’s modulus and responsiveness to the mechanical loading. Bone, 2013, 54: 35-43

[41] Pham PV et al. Targeting breast cancer stem cells by dendritic cell vaccination in humanized mice with breast tumor: preliminary results. Onco Targets Ther., 2016, 9: 4441-4451

[42] Bonar SL et al. Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. PLoS One, 2012, 7: e35979

[43] Valencia K et al. Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis. Clin. Cancer Res., 2012, 18: 969-980

[44] Ribot EJ et al. 3D anatomical and perfusion MRI for longitudinal evaluation of biomaterials for bone regeneration of femoral bone defect in rats. Sci. Rep., 2017, 7

[45] Hamamura K et al. Knee loading reduces MMP13 activity in the mouse cartilage. BMC Musculoskelet. Disord., 2013, 14

Funding

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(R01AR52144)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)(R03CA238555)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)

School of Medicine, Indiana University (IU School of Medicine)